ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer
ARID1A is an epigenetic regulator mutated in approximately 5% of non-hypermutated colorectal cancer tumors, however, its relationship with treatment response remains to be explored. Here, the authors suggest that ARID1A mutations may confer intrinsic and acquired resistance to cetuximab treatment.
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-09-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-022-33172-5 |
| _version_ | 1811265189408931840 |
|---|---|
| author | Radia M. Johnson Xueping Qu Chu-Fang Lin Ling-Yuh Huw Avinashnarayan Venkatanarayan Ethan Sokol Fang-Shu Ou Nnamdi Ihuegbu Oliver A. Zill Omar Kabbarah Lisa Wang Richard Bourgon Felipe de Sousa e Melo Chris Bolen Anneleen Daemen Alan P. Venook Federico Innocenti Heinz-Josef Lenz Carlos Bais |
| author_facet | Radia M. Johnson Xueping Qu Chu-Fang Lin Ling-Yuh Huw Avinashnarayan Venkatanarayan Ethan Sokol Fang-Shu Ou Nnamdi Ihuegbu Oliver A. Zill Omar Kabbarah Lisa Wang Richard Bourgon Felipe de Sousa e Melo Chris Bolen Anneleen Daemen Alan P. Venook Federico Innocenti Heinz-Josef Lenz Carlos Bais |
| author_sort | Radia M. Johnson |
| collection | DOAJ |
| description | ARID1A is an epigenetic regulator mutated in approximately 5% of non-hypermutated colorectal cancer tumors, however, its relationship with treatment response remains to be explored. Here, the authors suggest that ARID1A mutations may confer intrinsic and acquired resistance to cetuximab treatment. |
| first_indexed | 2024-04-12T20:17:57Z |
| format | Article |
| id | doaj.art-4488b89ca7bf43bdb1d09041a86d2a0c |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-04-12T20:17:57Z |
| publishDate | 2022-09-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-4488b89ca7bf43bdb1d09041a86d2a0c2022-12-22T03:18:03ZengNature PortfolioNature Communications2041-17232022-09-0113111310.1038/s41467-022-33172-5ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancerRadia M. Johnson0Xueping Qu1Chu-Fang Lin2Ling-Yuh Huw3Avinashnarayan Venkatanarayan4Ethan Sokol5Fang-Shu Ou6Nnamdi Ihuegbu7Oliver A. Zill8Omar Kabbarah9Lisa Wang10Richard Bourgon11Felipe de Sousa e Melo12Chris Bolen13Anneleen Daemen14Alan P. Venook15Federico Innocenti16Heinz-Josef Lenz17Carlos Bais18Bioinformatics & Computational Biology, Genentech, Inc.Oncology Biomarker Development, Genentech, Inc.Real World Data Science Analytics, Genentech, Inc.Oncology Biomarker Development, Genentech, Inc.Discovery Oncology, Genentech, Inc.Cancer Genomics Research, Foundation Medicine, Inc.Alliance Statistics and Data Management Center, Mayo ClinicGuardant Health, IncBioinformatics & Computational Biology, Genentech, Inc.Oncology Biomarker Development, Genentech, Inc.Real World Data Science Analytics, Genentech, Inc.Bioinformatics & Computational Biology, Genentech, Inc.Discovery Oncology, Genentech, Inc.Bioinformatics & Computational Biology, Genentech, Inc.Bioinformatics & Computational Biology, Genentech, Inc.University of California, San FranciscoUniversity of North Carolina at Chapel HillUSC Norris Comprehensive Cancer CenterOncology Biomarker Development, Genentech, Inc.ARID1A is an epigenetic regulator mutated in approximately 5% of non-hypermutated colorectal cancer tumors, however, its relationship with treatment response remains to be explored. Here, the authors suggest that ARID1A mutations may confer intrinsic and acquired resistance to cetuximab treatment.https://doi.org/10.1038/s41467-022-33172-5 |
| spellingShingle | Radia M. Johnson Xueping Qu Chu-Fang Lin Ling-Yuh Huw Avinashnarayan Venkatanarayan Ethan Sokol Fang-Shu Ou Nnamdi Ihuegbu Oliver A. Zill Omar Kabbarah Lisa Wang Richard Bourgon Felipe de Sousa e Melo Chris Bolen Anneleen Daemen Alan P. Venook Federico Innocenti Heinz-Josef Lenz Carlos Bais ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer Nature Communications |
| title | ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer |
| title_full | ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer |
| title_fullStr | ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer |
| title_full_unstemmed | ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer |
| title_short | ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer |
| title_sort | arid1a mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer |
| url | https://doi.org/10.1038/s41467-022-33172-5 |
| work_keys_str_mv | AT radiamjohnson arid1amutationsconferintrinsicandacquiredresistancetocetuximabtreatmentincolorectalcancer AT xuepingqu arid1amutationsconferintrinsicandacquiredresistancetocetuximabtreatmentincolorectalcancer AT chufanglin arid1amutationsconferintrinsicandacquiredresistancetocetuximabtreatmentincolorectalcancer AT lingyuhhuw arid1amutationsconferintrinsicandacquiredresistancetocetuximabtreatmentincolorectalcancer AT avinashnarayanvenkatanarayan arid1amutationsconferintrinsicandacquiredresistancetocetuximabtreatmentincolorectalcancer AT ethansokol arid1amutationsconferintrinsicandacquiredresistancetocetuximabtreatmentincolorectalcancer AT fangshuou arid1amutationsconferintrinsicandacquiredresistancetocetuximabtreatmentincolorectalcancer AT nnamdiihuegbu arid1amutationsconferintrinsicandacquiredresistancetocetuximabtreatmentincolorectalcancer AT oliverazill arid1amutationsconferintrinsicandacquiredresistancetocetuximabtreatmentincolorectalcancer AT omarkabbarah arid1amutationsconferintrinsicandacquiredresistancetocetuximabtreatmentincolorectalcancer AT lisawang arid1amutationsconferintrinsicandacquiredresistancetocetuximabtreatmentincolorectalcancer AT richardbourgon arid1amutationsconferintrinsicandacquiredresistancetocetuximabtreatmentincolorectalcancer AT felipedesousaemelo arid1amutationsconferintrinsicandacquiredresistancetocetuximabtreatmentincolorectalcancer AT chrisbolen arid1amutationsconferintrinsicandacquiredresistancetocetuximabtreatmentincolorectalcancer AT anneleendaemen arid1amutationsconferintrinsicandacquiredresistancetocetuximabtreatmentincolorectalcancer AT alanpvenook arid1amutationsconferintrinsicandacquiredresistancetocetuximabtreatmentincolorectalcancer AT federicoinnocenti arid1amutationsconferintrinsicandacquiredresistancetocetuximabtreatmentincolorectalcancer AT heinzjoseflenz arid1amutationsconferintrinsicandacquiredresistancetocetuximabtreatmentincolorectalcancer AT carlosbais arid1amutationsconferintrinsicandacquiredresistancetocetuximabtreatmentincolorectalcancer |